Episode summary
CVS Plans to Break Up $117 Billion Healthcare Conglomerate | Bloomberg Intelligence
Bloomberg Intelligence
· · 12 min · Hosts: Paul Sweeney, Scarlet Fu · Guests: John Tozzi, Mandeep Singh
Summary
CVS said it will spin off its retail pharmacy chain into a separate company, CVS Pharmacy, in the first half of 2028, while keeping Aetna and Caremark inside CVS Health. The guest said the move is a sharp break from the company’s long-running strategy of integrating retail, insurance, and pharmacy benefits, and the market’s negative reaction suggests investors are unsure the standalone math works. CVS shares fell as much as 14% after the announcement, reflecting concern that the new pharmacy company would be low-growth, low-margin, and burdened with duplicated overhead.
The guest said CVS’s logic is that the retail pharmacy business may be better off on its own as retail pharmacies continue to struggle, but he also noted the company had just told investors the integrated model was an advantage. He argued the decision looks abrupt and possibly reactive, especially given management’s recent emphasis on app-driven integration across businesses.
The second half of the show shifted to tech. An analyst said election outcomes could slow data-center permitting and trim 2027 capex by 5% to 7%, which he framed as supportive for hyperscaler free cash flow. He also said Uber faces rising R&D spending and pressure on pricing, while AMD’s stronger AI-chip demand and better data-center exposure explain why its outlook looks far better than Intel’s.
Key takeaways
- CVS plans to separate CVS Pharmacy from Aetna and Caremark, and the guest said the market is questioning whether the breakup creates value or just duplicates overhead.
- The guest said CVS’s retail footprint is increasingly hard to justify in a retail environment that has been under pressure for years.
- An analyst said election-driven permitting friction could reduce 2027 data-center capex by 5% to 7%, which would improve hyperscaler free cash flow.
- The analyst said Uber’s R&D rose 48% in the quarter as it ramps AI and autonomous-vehicle investment, while pricing pressure and more competition could compress margins.
- The analyst said AMD’s AI-chip demand and data-center exposure are driving a much stronger outlook than Intel’s.
- The analyst said a more spread-out capex cycle could avoid a future buildout cliff in data centers.
Notable quotes
“the retail pharmacy business into a new company while keeping its Etna insurance and Caremark prescription benefits division as CVS Health”
“the market doesn't believe that”
“2027 capex could be revised lower by 5 to 7%”
“R&D for Uber grew 48% in the quarter”
How the episode opens
Bloomberg Audio Studios, podcasts, radio, news. You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10 a.m. Eastern on Apple CarPlay and Android Auto with the Bloomberg Business App. — Listen on demand wherever you get your podcasts or watch us live on YouTube. As promised, we want to get to this big news out of CVS, breaking up its gigantic business, spinning off the retail pharmacy business into a new company while keeping its Etna insurance and Caremark prescription benefits division as CVS Health. John Tazy is our Bloomberg healthcare reporter and joins us now. Is this an experiment that just kind of went wrong?
Um, well, I don't think we know yet. Um CVS is unlike most of its peers in that it does have a big retail pharmacy chain. Um that's what the company is most known for.
Um but you know uh it also has as you said Etna giant insurance company that they bought about uh seven or eight years ago. Um and the pharmacy benefits manager so running prescription drug plans. um most of its peers which are now companies like United Health, Sigma, um Elevance Health don't have that retail pharmacy footprint.
So they are a little unique in that uh in that respect and retailies have struggled uh in recent years as we've seen with Wraid and Walgreens.
When this deal was announced, I remember saying I don't get it. I just don't get it. What was the industrial logic for putting these companies together?
Um you know so the current kind of CVS enterprise was assembled over a number of deals over you know the last 20 years um from the retail stores adding the pharmacy benefits manager you can see um some uh synergies there right where you have you're dealing with people's prescription drug plans on one end and then you're dispensing their medications on the other um adding Etna more recently um kind of brings them into all you know kind of across the supply chain as it were of of healthcare I think the question for the company now is does it make sense uh to have a big retail footprint in an era when retail is challenged.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- cvs spinoff
- healthcare consolidation
- midterm elections tech sector
- uber earnings
- amd data center demand
Companies and tickers mentioned
- CVS
- UBER
- AMD
- CVS Health
- Aetna
- CVS Pharmacy
- Caremark
- Uber Technologies
- Advanced Micro Devices
Watch the episode
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Bloomberg Intelligence
-
Anthropic’s IPO Is Said to Be About Six Times Oversubscribed | Bloomberg Intelligence -
Instant Reaction: Nvidia CEO Jensen Huang Ousted by Nvidia Board | Bloomberg Intelligence -
Nvidia’s Huang Ousted by Board in Move That Roils AI Economy | Bloomberg Intelligence -
CoreWeave Shares Soar After AI Computing Firm Eases Debt Fears | Bloomberg Intelligence -
Anthropic Targets $1.4 Trillion Valuation in Blockbuster IPO | Bloomberg Intelligence -
Nvidia Probe Into CEO Affair Raises Thorny Questions for AI | Bloomberg Intelligence
Bloomberg Intelligence, this episode and its artwork belong to Bloomberg. Octagon is not affiliated with the show; this page is an independent summary.
